AstraZeneca: Fasenra Trial In EoE Did Not Meet One Of Two Dual-primary Endpoints
25/10 08:20
(RTTNews) - British drug major AstraZeneca PLC (AZN.L) Tuesday announced that MESSINA Phase III trial for Fasenra (benralizumab) failed to meet one of the two dual-primary endpoints in eosinophilic esophagitis....